Population pharmacokinetics of ondansetron: a covariate analysis.

AIMS To construct a population model to account for the variability in ondansetron pharmacokinetics and to evaluate methods for the efficient development of population models. METHODS Population models were developed using 99 subjects consisting of paediatric patients, young, elderly and aged volunteers. A two compartment pharmacokinetic model with a zero order input was used to describe the pharmacokinetics of ondansetron. Three stepwise methods were proposed and used alongside a three step approach to develop population models with both rich and sparse data sets. The stepwise methods were based on obtaining empirical Bayes posterior estimates of pharmacokinetic parameters within a nonlinear mixed effect modelling (NONMEM) program. The parameters were then regressed against covariates in a stepwise procedure. Variance parameters were obtained by fitting the proposed population model to the data in one further NONMEM run. The population model was validated against a test data set of 54 subjects, including children, young and elderly patients and volunteers. RESULTS The population model adequately described the differences in ondansetron pharmacokinetics between paediatric patients, young, elderly and aged volunteers. Different covariates were identified by the various methods. Weight was found to have a strong positive linear relationship with all four pharmacokinetic parameters. Clearance showed a weak negative relationship with age. Males were found to have a greater clearance than females after weight adjustment. CONCLUSIONS The stepwise search procedures potentially are capable of considerably reducing the time required to develop population pharmacokinetic models. The model developed for ondansetron gave accurate predictions of both the concentration-time profile and variability in an independent data set.

[1]  A. Vickers,et al.  The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[2]  A. Markham,et al.  Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. , 1993, Drugs.

[3]  M. Tarbit,et al.  Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[4]  J. Lerman,et al.  Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery , 1995, Clinical pharmacology and therapeutics.

[5]  A. Bedding,et al.  The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. , 1994, British journal of clinical pharmacology.

[6]  C. Felgate,et al.  Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. , 1991, Journal of pharmaceutical sciences.

[7]  J. Powell,et al.  Age and gender effects on ondansetron pharmacokinetics: Evaluation of healthy aged volunteers , 1992, Clinical pharmacology and therapeutics.

[8]  M. A. Mergener,et al.  Pharmacokinetics of the Digoxin-Quinidine Interaction via Mixed-Effect Modelling , 1992, Clinical pharmacokinetics.

[9]  J. Pritchard Ondansetron metabolism and pharmacokinetics. , 1992, Seminars in oncology.

[10]  B. Efron,et al.  A Leisurely Look at the Bootstrap, the Jackknife, and , 1983 .

[11]  J. Powell,et al.  Pharmacokinetics of Ondansetron in Patients with Hepatic Insufficiency , 1996, Journal of clinical pharmacology.

[12]  A. Huang,et al.  Oral Ondansetron Pharmacokinetics: The Effect of Chemotherapy , 1994, Journal of clinical pharmacology.

[13]  Thomas M. Ludden,et al.  Pharmacokinetics of Quinidine in Male Patients , 1992, Clinical pharmacokinetics.